In a setback for Viatris and Mapi Pharma, the U.S. FDA has chosen not to approve their once-a-month injection for treating relapsing forms of multiple sclerosis (MS), a debilitating neurological condition. The decision was communicated through a complete response letter (CRL), indicating that the application would require additional information before it can be approved in its present form. Both companies are currently evaluating the contents of the letter to determine the next steps in the regulatory process.
The injection in question, known as GA Depot, is a long-acting version of glatiramer acetate, an existing treatment for relapsing forms of MS. Unlike other treatments like Teva Pharmaceutical Industries' Copaxone, which requires thrice-weekly injections, GA Depot was designed to be administered as a monthly intramuscular injection. Viatris had obtained commercialization rights to GA Depot through an exclusive license agreement with Mapi Pharma back in 2018.
While the receipt of the FDA's CRL is undoubtedly a setback for the companies, Viatris has stated that it will not impact its financial forecasts for 2024 or its projections for new product revenue, which are expected to fall within the range of $450 million to $550 million. Despite the setback, Viatris remains committed to advancing treatments for MS and other neurological conditions.
MS is a chronic autoimmune disease in which the immune system targets the brain and spinal cord, leading to a range of symptoms including motor disabilities. In the United States alone, approximately 400,000 individuals are affected by MS, according to data from the National Institutes of Health. Relapsing MS, the form of the disease targeted by GA Depot, is characterized by periods of symptom flare-ups followed by periods of remission, during which the disease is relatively inactive.
As Viatris and Mapi Pharma navigate the FDA's feedback and work towards addressing the concerns raised in the CRL, the focus remains on developing effective and accessible treatments for individuals living with MS. Collaborative efforts between pharmaceutical companies, regulatory agencies, and patient communities are crucial in advancing the field of MS therapeutics and ultimately improving the quality of life for those impacted by this neurologically complex condition.